Loading...
•
Sep 30, 2021
Orthofix Q3 2021 Earnings Report
Reported net sales of $112 million with adjusted EPS of $0.10.
Key Takeaways
Orthofix Medical Inc. reported a 1.3% increase in net sales to $112 million for the quarter ended September 30, 2021. The company's EPS was $(0.11), and adjusted EPS was $0.10.
Net sales increased by 1.3% over the prior year period, reaching $112 million.
Global Spinal Implants and Orthopedics businesses experienced double-digit growth.
Over 60,000 M6-C artificial cervical discs have been implanted worldwide.
AccelStim PMA application was submitted for healing fresh fractures.
Revenue by Segment
Forward Guidance
The Company expects net sales between $460.0 and $464.0 million for the year ended December 31, 2021.
Positive Outlook
- Continued strength of the M6-C disc.
- Growth of the FITBONE system.
- Recently bolstered 3D-printed titanium spinal interbody portfolio.
- Diversification of biologics portfolio with products like Opus Mg Set.
- Planned expansion of bone growth therapy portfolio with AccelStim.
Challenges Ahead
- Ongoing challenges of COVID on operations and financial results.
- Potential delays or cancellations of surgeries due to hospital limitations.
- Possible workforce disruptions due to illness, quarantines, or government actions.
- Potential disruptions to the supply chain.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...